Notably, our clinical findings were supported by data from the gp130F/F preclinical GC model, in which NLRP3 deficiency had no impact on tumor burden or well-documented tumor-promoting cellular processes, namely, cell proliferation and survival, inflammation, and angiogenesis. The gene discussed is NLRP3; the disease is gastric cancer.